Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus

Orem, UT—Dymicron, Inc., (dymicron.com) confirmed the successful completion of their first in-human surgeries using their unique Triadyme-C cervical total disc replacement device. The two surgeries were performed by noted surgeon Dr. William D. Smith at the American Institute of Minimally Invasive Surgery (AIMIS) in Cyprus.

“The patients are responding well to the implantation of the Dymicron devices,” said Dr. William D. Smith, Chairman of AIMIS Spine Center and Chief of Neurosurgery for the University Medical Center, Las Vegas, Nevada. “The Triadyme-C is unique in its composition and design, most notably for its diamond compact. This design may place Dymicron as a front runner in cervical TDR devices in a time when research has shown cervical TDR is often superior to fusion.”

The Triadyme-C is the flagship product of Dymicron, Inc., a company focused on designing, developing and commercializing medical devices leveraging their proprietary Orthopedic DiamondTM material.

Triadyme-C will address two immediate areas of concern in the total disc replacement field – minimizing wear debris generation and emulation of natural constrained motion in the spine.

Dymicron’s biocompatible Orthopedic Diamond material is made of polycrystalline diamond compact (PDC), one of the hardest and most durable substances known to man. With extreme durability and a low coefficient of friction, Triadyme-C resists the structural breakdown that can release dangerous wear debris into the body.

The proprietary tri-lobe technology developed by Dymicron features an articulation mechanism made of three spherical lobes seated within three non-congruent, spherical pockets. The motion of the three lobes within their associated pockets generates a smooth, gentle centering force that emulates the natural motion of the spine.

“We are extremely pleased that we have successfully completed our first in-man procedures. Based on our unique technology and design, we’re confident that the Triadyme-C will become a preferred option for patients suffering from cervical degenerative disc disease,” said Jeff Bennett, President of Dymicron.

Following the successful completion of the first in-human procedures, Dymicron is slated to begin three clinical studies in England, Germany and South Africa in Q3 of 2015.